Rye, N.Y. — Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, has completed its targeted enrollment of Phase III clinical trials for CM-AT, its autism treatment.
According to a release, Curemark has reached its targeted enrollment for the study of a total 170 children, who are participating in the CM-AT Phase III trial at 18 sites across the country.
"We have been extremely pleased with the enthusiastic response of our clinical sites during the CM-AT Phase III trial process. We now have the full complement of trial participants and will close the trial to enrollment and begin the compilation process for FDA submissions," stated Dr. Bill Gannon, Curemark's Medical Director.
"This marks a significant milestone for us and our research program," said Dr. Joan Fallon, Curemark founder and CEO. "We are grateful to our clinical sites for their participation."
CM-AT targets enzyme deficiencies in autistic children. These deficiencies affect the availability of amino acids, the building blocks of chemicals that are essential for brain function. Curemark's autism therapy has received Fast Track review status from the FDA.
- EEGs used to diagnose autism in infants
- Dan Marino, Samsung launch "Team Up for Autism"
- DRG partners with autism treatment center
- Study linking autism to MMR vaccine a fraud?
- Early intervention shown to improve autism symptoms
- Medicaid expenditures for autism on rapid rise
- Brain Balance Centers provides change for children with autism
- Danya to unveil online resource for autism research products
- Class action filed over refusal to pay for autism ABA therapy
- Charity golf event to support Autism Research Collaboration
- Contribution supports Central Ohio school focused on autism
- Military families file lawsuit against DoD for refusing to pay for autism treatment